| Year |
Citation |
Score |
| 2024 |
Bacharier LB, Pavord ID, Maspero JF, Jackson DJ, Fiocchi AG, Mao X, Jacob-Nara JA, Deniz Y, Laws E, Mannent LP, Amin N, Akinlade B, Staudinger HW, Lederer DJ, Hardin M. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma. The Journal of Allergy and Clinical Immunology. PMID 38272375 DOI: 10.1016/j.jaci.2023.09.044 |
0.315 |
|
| 2023 |
Bacharier LB, Guilbert TW, Katelaris CH, Deschildre A, Phipatanakul W, Liu D, Altincatal A, Mannent LP, Amin N, Laws E, Akinlade B, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, et al. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study. The Journal of Allergy and Clinical Immunology. in Practice. PMID 38092225 DOI: 10.1016/j.jaip.2023.12.006 |
0.357 |
|
| 2023 |
Corren J, Hanania NA, Busse WW, Sher LD, Altincatal A, Hardin M, Mannent LP, Amin N, Lederer DJ, Soler X, Jacob-Nara JA, Rowe PJ, Deniz Y. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization. Clinical and Experimental Allergy : Journal of the British Society For Allergy and Clinical Immunology. 53: 1020-1030. PMID 37752621 DOI: 10.1111/cea.14389 |
0.402 |
|
| 2023 |
Bachert C, Laidlaw TM, Cho SH, Mullol J, Swanson BN, Naimi S, Classe M, Harel S, Jagerschmidt A, Laws E, Ruddy M, Praestgaard A, Amin N, Mannent LP. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results. The Annals of Otology, Rhinology, and Laryngology. 34894231176334. PMID 37322842 DOI: 10.1177/00034894231176334 |
0.326 |
|
| 2023 |
Jackson DJ, Bacharier LB, Phipatanakul W, Sher L, Domingo C, Papadopoulos N, Modena B, Li N, Xia C, Kamal MA, Dillon M, Wolfe K, Gall R, Amin N, Mannent LP, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. PMID 36958470 DOI: 10.1016/j.anai.2023.03.014 |
0.424 |
|
| 2022 |
Canonica GW, Bourdin A, Peters AT, Desrosiers M, Bachert C, Weidinger S, Simpson EL, Daizadeh N, Chen Z, Kamat S, Khan AH, Chao J, Graham NMH, Laws E, Rossi AB, ... ... Amin N, et al. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases. The Journal of Allergy and Clinical Immunology. in Practice. PMID 35259535 DOI: 10.1016/j.jaip.2022.02.026 |
0.334 |
|
| 2021 |
Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, Zhang Y, Khan AH, Kapoor U, Khokhar FA, Rowe PJ, ... ... Amin N, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. The New England Journal of Medicine. 385: 2230-2240. PMID 34879449 DOI: 10.1056/NEJMoa2106567 |
0.388 |
|
| 2021 |
Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. The New England Journal of Medicine. 385: 1656-1668. PMID 34706171 DOI: 10.1056/NEJMoa2024257 |
0.427 |
|
| 2021 |
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, ... ... Amin N, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. The Lancet. Respiratory Medicine. PMID 34597534 DOI: 10.1016/S2213-2600(21)00322-2 |
0.424 |
|
| 2021 |
Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, Maspero JF, Picado C, Daizadeh N, Ortiz B, Li Y, Ruddy M, Laws E, Amin N. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy. PMID 34459002 DOI: 10.1111/all.15067 |
0.303 |
|
| 2021 |
Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, Staudinger H, Horowitz JE, Baras A, Ferreira MA, Ruddy MK, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. The Lancet. Respiratory Medicine. PMID 34302758 DOI: 10.1016/S2213-2600(21)00167-3 |
0.377 |
|
| 2021 |
Maspero JF, FitzGerald JM, Pavord ID, Rice MS, Maroni J, Rowe PJ, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A, Hardin M. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. PMID 33905544 DOI: 10.1111/all.14872 |
0.425 |
|
| 2021 |
Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J, Maspero JF, Gevaert P, Zhang M, Mao X, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, et al. Dupilumab improves upper- and lower-airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. PMID 33465455 DOI: 10.1016/j.anai.2021.01.012 |
0.421 |
|
| 2020 |
Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic Rhinosinusitis With Nasal Polyps and Asthma. The Journal of Allergy and Clinical Immunology. in Practice. PMID 33065369 DOI: 10.1016/j.jaip.2020.09.063 |
0.481 |
|
| 2020 |
Busse WW, Maspero JF, Lu Y, Corren J, Hanania NA, Chipps BE, Katelaris CH, FitzGerald JM, Quirce S, Ford LB, Rice MS, Kamat S, Khan AH, Jagerschmidt A, Harel S, ... ... Amin N, et al. Dupilumab improves clinical outcomes in patients with asthma and perennial allergic rhinitis. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. PMID 32474156 DOI: 10.1016/J.Anai.2020.05.026 |
0.571 |
|
| 2020 |
Castro M, Rabe KF, Corren J, Pavord ID, Katelaris CH, Tohda Y, Zhang B, Rice MS, Maroni J, Rowe P, Pirozzi G, Amin N, Ruddy M, Akinlade B, Graham NMH, et al. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. Erj Open Research. 6. PMID 32010719 DOI: 10.1183/23120541.00204-2019 |
0.545 |
|
| 2020 |
Castro M, Corren J, Casale T, Quirce S, Rice, Deniz Y, Rowe P, Amin N, Teper A. Dupilumab Effect on Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma with an Allergic Phenotype Pneumologie. 74: 100. DOI: 10.1055/S-0039-3403258 |
0.521 |
|
| 2020 |
Corren J, Sher L, Zhu X, Rice, Deniz Y, Rowe P, Staudinger H, Ruddy M, Patel N, Graham N, Teper A, Amin N. Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Asthma and Serologic Evidence of Allergic Bronchopulmonary Aspergillosis Pneumologie. 74: 99. DOI: 10.1055/S-0039-3403257 |
0.567 |
|
| 2020 |
Rabe K, FitzGerald J, Bateman E, Castro M, Pavord I, Maspero J, Busse W, Rice M, Deniz Y, Rowe P, Patel N, Amin N, Ruddy M, Graham N, Teper A. Dupilumab Efficacy in GINA-Defined Difficult-to-Treat Type 2 Asthma Patients The Journal of Allergy and Clinical Immunology. 145. DOI: 10.1016/J.Jaci.2019.12.785 |
0.544 |
|
| 2020 |
Mullol J, Han J, Bosso J, Mannent L, Amin N, Cho S, Bachert C. Dupilumab Treatment Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps – Pooled Results From the SINUS-24 and SINUS-52 Phase 3 Trials Journal of Allergy and Clinical Immunology. 145: AB169. DOI: 10.1016/J.Jaci.2019.12.349 |
0.37 |
|
| 2020 |
Bachert C, Cho S, Laidlaw T, Swanson B, Harel S, Mannent L, Amin N, Jagerschmidt A. Dupilumab Reduces Blood, Urine, and Nasal Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyps in the Phase 3 SINUS-52 Trial Journal of Allergy and Clinical Immunology. 145: AB185. DOI: 10.1016/J.Jaci.2019.12.324 |
0.383 |
|
| 2020 |
Han J, Gross G, Mannent L, Amin N, Cho S, Bachert C. Dupilumab Improves Sinus Opacification in All Sinuses in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Results From the SINUS-24 Phase 3 Study Journal of Allergy and Clinical Immunology. 145: AB251. DOI: 10.1016/J.Jaci.2019.12.109 |
0.405 |
|
| 2019 |
Bachert C, Zinreich SJ, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Amin N, Joish VN, Fan C, Zhang D, Staudinger H, Pirozzi G, Graham NMH, Khan A, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. PMID 31671432 DOI: 10.4193/Rhin18.282 |
0.355 |
|
| 2019 |
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet (London, England). PMID 31543428 DOI: 10.1016/S0140-6736(19)31881-1 |
0.449 |
|
| 2019 |
Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan A, Kamat S, Maroni J, ... ... Amin N, et al. Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma. The Journal of Allergy and Clinical Immunology. in Practice. PMID 31521831 DOI: 10.1016/J.Jaip.2019.08.050 |
0.569 |
|
| 2019 |
Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, ... ... Amin N, et al. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma With Self-reported Chronic Rhinosinusitis. The Journal of Allergy and Clinical Immunology. in Practice. PMID 31351189 DOI: 10.1016/J.Jaip.2019.07.016 |
0.543 |
|
| 2019 |
Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Joish VN, Chao J, Mannent L, Amin N, Abbe A, Taniou C, Fan C, Pirozzi G, Graham NMH, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. PMID 31306495 DOI: 10.1111/All.13984 |
0.334 |
|
| 2019 |
Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, Khan A, Eckert L, Teper A. Dupilumab Improves Asthma Outcomes Irrespective of Frequency of Previous Asthma Exacerbation History. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. PMID 31075309 DOI: 10.1016/J.Anai.2019.04.028 |
0.504 |
|
| 2019 |
Laidlaw TM, Mullol J, Fan C, Zhang D, Amin N, Khan A, Chao J, Mannent LP. Dupilumab Improves Nasal Polyp Burden and Asthma Control in Patients With CRSwNP and AERD. The Journal of Allergy and Clinical Immunology. in Practice. PMID 30954643 DOI: 10.1016/J.Jaip.2019.03.044 |
0.551 |
|
| 2019 |
Bachert C, Hellings PW, Mullol J, Naclerio RM, Chao J, Amin N, Grabher A, Swanson BN, Hamilton JD, Guillonneau S, Taniou C, Zhang D, Pirozzi G, Graham NMH, Staudinger H, et al. Dupilumab improves patient reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. The Journal of Allergy and Clinical Immunology. in Practice. PMID 30928658 DOI: 10.1016/J.Jaip.2019.03.023 |
0.515 |
|
| 2019 |
Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N, Rowe P, Maroni J, Eckert L, Yang T, Khan A. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. The Laryngoscope. PMID 30720213 DOI: 10.1002/Lary.27852 |
0.326 |
|
| 2019 |
Mullol J, Laidlaw TM, Amin N, Bachert C, Han JK, Hellings PW, Canonica GW, Cho SH, Maspero JF, Desrosiers M, Hopkins C, Paggiaro P, Zhang M, Lu X, Patel N, et al. Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials European Respiratory Journal. 54. DOI: 10.1183/13993003.Congress-2019.Rct3783 |
0.373 |
|
| 2019 |
Castro M, Corren J, Casale TB, Quirce S, Rice MS, Deniz Y, Rowe P, Amin N, Teper A. Dupilumab Effect on Lung Function in Patients With Uncontrolled, Moderate-to-Severe Asthma With an Allergic Phenotype European Respiratory Journal. DOI: 10.1183/13993003.Congress-2019.Pa540 |
0.521 |
|
| 2019 |
Laidlaw TM, Mullol J, Canonica GW, Bachert C, Han JK, Zhang M, Lu X, Patel N, Graham NM, Staudinger H, Mannent LP, Amin N. Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials European Respiratory Journal. DOI: 10.1183/13993003.Congress-2019.Pa539 |
0.389 |
|
| 2019 |
Papi A, Pavord ID, Fitzgerald JM, Corren J, Bardin P, Park HS, Rice MS, Deniz Y, Rowe P, Staudinger H, Amin N, Ruddy M, Graham NMH, Teper A. Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: liberty asthma quest Study European Respiratory Journal. DOI: 10.1183/13993003.Congress-2019.Pa538 |
0.521 |
|
| 2019 |
Carr W, Jackson DJ, Corren J, Bergmann K, Rice MS, Deniz Y, Rowe P, Amin N, Teper A. Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Asthma by Immunoglobin E Levels at Baseline European Respiratory Journal. DOI: 10.1183/13993003.Congress-2019.Pa536 |
0.522 |
|
| 2019 |
Korn S, Busse WW, Echave-Sustaeta JM, Dixon AE, Mucsi J, Rice MS, Deniz Y, Rowe P, Staudinger HW, Amin N, Ruddy M, Graham NMH, Teper A. Dupilimab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Asthma by Body Mass Index European Respiratory Journal. DOI: 10.1183/13993003.Congress-2019.Pa2753 |
0.49 |
|
| 2019 |
Pavord ID, Fitzgerald JM, Brusselle G, Wenzel SE, Rabe KF, Busse WW, Papi A, Rice MS, Deniz Y, Rowe P, Amin N, Graham NMH, Teper A. Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study European Respiratory Journal. DOI: 10.1183/13993003.Congress-2019.Oa3807 |
0.532 |
|
| 2019 |
Paggiaro P, Castro M, Canonica W, Douglass J, Tohda Y, Rice, Deniz Y, Rowe P, Amin N, Teper A. S49 Dupilumab improves lung function across baseline disease characteristics in patients with evidence of type 2 inflammation at baseline: the LIBERTY ASTHMA QUEST study Thorax. 74. DOI: 10.1136/Thorax-2019-Btsabstracts2019.55 |
0.518 |
|
| 2019 |
Busse W, Muñoz X, Casale T, Paggiaro P, Castro M, Tohda Y, Rice, Deniz Y, Rowe P, Amin N, Teper A. S31 Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study Thorax. 74. DOI: 10.1136/Thorax-2019-Btsabstracts2019.37 |
0.556 |
|
| 2019 |
Bachert C, Desrosiers M, Mullol J, Maspero J, Wagenmann M, Niemann I, Khan A, Kamat S, Amin N, Mannent L. Baseline Characteristics of Patients With Chronic Rhinosinusitis With Nasal Polyps (With and Without Asthma) Enrolled in SINUS-52, a Randomized, Double-Blind, Phase 3 Study of Dupilumab Laryngo-Rhino-Otologie. 98: 11230. DOI: 10.1055/S-0039-1686710 |
0.547 |
|
| 2019 |
Bachert C, Desrosiers M, Mullol J, Hellings PW, Cervin A, Sher L, Bosso JV, Lee SE, Maspero JF, Fujieda S, Matsune S, Lu X, Fan C, Draikiwicz S, Amin N, et al. A Randomized Phase 3 Study, Sinus-52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps Journal of Allergy and Clinical Immunology. 143: AB433. DOI: 10.1016/J.Jaci.2018.12.980 |
0.38 |
|
| 2019 |
Han JK, Bachert C, Desrosiers M, Laidlaw TM, Hopkins C, Fokkens WJ, Paggiaro P, Ho Cho S, Olze H, Greos LS, Zhang M, Fan C, Draikiwicz S, Amin N, Kamat S, et al. Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study Journal of Allergy and Clinical Immunology. 143: AB422. DOI: 10.1016/J.Jaci.2018.12.948 |
0.363 |
|
| 2019 |
Bousquet J, Maspero JF, Chipps BE, Corren J, FitzGerald JM, Chen Z, Lu Y, Rowe P, Staudinger H, Ruddy M, Graham NMH, Kamat S, Amin N, Teper A, Khan A. Dupilumab Consistently Improves Rhinoconjunctivitis-Specific Health-Related Quality of Life in Patients With Uncontrolled, Moderate-to-Severe Asthma and Comorbid Allergic Rhinitis: Results from the Phase 3 LIBERTY ASTHMA QUEST Study The Journal of Allergy and Clinical Immunology. 143. DOI: 10.1016/J.Jaci.2018.12.307 |
0.535 |
|
| 2019 |
Maspero JF, Corren J, Ford LB, Sher L, Chipps BE, Peters AT, Rice M, Rowe P, Lu Y, Harel S, Staudinger H, Amin N, Ruddy M, Graham NMH, Teper A. Dupilumab Suppresses Type 2 Biomarkers in Asthma Patients With and Without Comorbid Chronic Rhinosinusitis With or Without Nasal Polyposis (CRS/NP): Post Hoc Analysis of LIBERTY ASTHMA QUEST The Journal of Allergy and Clinical Immunology. 143. DOI: 10.1016/J.Jaci.2018.12.299 |
0.534 |
|
| 2019 |
Corren J, Bousquet J, Busse WW, Maspero JF, Hanania NA, Ford LB, Rice M, Lu Y, Rowe P, Harel S, Staudinger H, Ruddy M, Graham NMH, Amin N, Teper A. Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study The Journal of Allergy and Clinical Immunology. 143. DOI: 10.1016/J.Jaci.2018.12.297 |
0.548 |
|
| 2019 |
Busse WW, Maspero JF, Hanania NA, FitzGerald JM, Ford LB, Rice M, Lu Y, Rowe P, Staudinger H, Amin N, Ruddy M, Graham NMH, Teper A. Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study The Journal of Allergy and Clinical Immunology. 143. DOI: 10.1016/J.Jaci.2018.12.296 |
0.562 |
|
| 2019 |
Gevaert P, Bachert C, Desrosiers M, Mullol J, Maspero J, Zhang M, Mao X, Kamat S, Khan A, Amin N, Staudinger H, Mannent L. P452 Dupilumab Improves Patient-Reported Outcomes In Chronic Rhinosinusitis With Nasal Polyps And Comorbid Asthma: Sinus-24/Sinus-52 Trials Annals of Allergy Asthma & Immunology. 123. DOI: 10.1016/J.Anai.2019.08.343 |
0.503 |
|
| 2019 |
Corren J, Sher L, Zhu X, Rice M, Deniz Y, Rowe P, Staudinger H, Ruddy M, Patel N, Graham N, Teper A, Amin N. D201 Dupilumab Efficacy In Patients With Uncontrolled, Moderate-To-Severe Asthma And Serologic Evidence Of Allergic Bronchopulmonary Aspergillosis Annals of Allergy Asthma & Immunology. 123. DOI: 10.1016/J.Anai.2019.08.071 |
0.53 |
|
| 2018 |
Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbé A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. PMID 30138668 DOI: 10.1016/J.Anai.2018.08.005 |
0.542 |
|
| 2018 |
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. The New England Journal of Medicine. PMID 29782224 DOI: 10.1056/Nejmoa1804093 |
0.478 |
|
| 2018 |
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, ... Amin N, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. The New England Journal of Medicine. PMID 29782217 DOI: 10.1056/Nejmoa1804092 |
0.545 |
|
| 2018 |
Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Advances in Therapy. PMID 29725983 DOI: 10.1007/S12325-018-0702-4 |
0.545 |
|
| 2018 |
Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. The Journal of Allergy and Clinical Immunology. PMID 29355679 DOI: 10.1016/J.Jaci.2017.11.051 |
0.476 |
|
| 2018 |
Wenzel S, Pavord ID, Rabe KF, Papi A, Fitzgerald JM, Jagerschmidt A, Brian W, Dong Q, Swanson BN, Hamilton JD, Amin N, Pirozzi G, Ruddy M, Akinlade B, GN, et al. Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST European Respiratory Journal. 52. DOI: 10.1183/13993003.Congress-2018.Pa5005 |
0.545 |
|
| 2018 |
Rabe KF, Brusselle G, Castro M, Sher L, Zhu H, Dong Q, Hamilton JD, Brian W, Jagerschmidt A, Pirozzi G, Amin N, Ruddy M, Akinlade B, Graham NMH, Teper A. Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in LIBERTY ASTHMA VENTURE European Respiratory Journal. 52. DOI: 10.1183/13993003.Congress-2018.Pa5003 |
0.535 |
|
| 2018 |
Busse W, Maspero JF, Katelaris CH, Saralaya D, Guillonneau S, Zhang B, Taniou C, Staudinger H, Chao J, Amin N, Pirozzi G, Ruddy M, Akinlade B, Graham NMH, Teper A, et al. Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST European Respiratory Journal. 52. DOI: 10.1183/13993003.Congress-2018.Pa1125 |
0.494 |
|
| 2018 |
Corren J, Castro M, Maspero JF, Santiago ALV, Kuna P, Guillonneau S, Dong Q, Taniou C, Staudinger H, Chao J, Amin N, Pirozzi G, Ruddy M, Akinlade B, Graham NMH, et al. Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis(CRS/NP) in LIBERTY ASTHMA QUEST European Respiratory Journal. 52. DOI: 10.1183/13993003.Congress-2018.Pa1124 |
0.507 |
|
| 2018 |
Pavord ID, Ford L, Sher L, Rabe KF, Park H, Cosio BG, Foster MC, Staudinger H, Maroni J, Rowe P, Amin N, Pirozzi G, Ruddy M, Akinlade B, Graham NMH, et al. Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST European Respiratory Journal. 52. DOI: 10.1183/13993003.Congress-2018.Oa1651 |
0.467 |
|
| 2018 |
Pavord I, Papi A, Wenzel S, Park H, Rice M, Staudinger H, Maroni J, Rowe P, Rout R, Amin N, Akinlade B, Graham N, Teper A. S78 Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study Thorax. 73. DOI: 10.1136/Thorax-2018-212555.84 |
0.525 |
|
| 2018 |
Pavord I, Ford L, Corren J, Kuna P, Dong Q, Staudinger H, Maroni J, Rowe P, Rout R, Amin N, Akinlade B, Graham N, Teper A. P44 Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study Thorax. 73. DOI: 10.1136/Thorax-2018-212555.202 |
0.571 |
|
| 2018 |
Castro M, Swanson BN, Jayawardena S, Hamilton JD, Amin N, Pirozzi G, Graham NMH, Teper A. Exacerbation Risk and Type 2 Inflammation in Placebo Patients During a Phase 2b Study of Dupilumab in Patients With Uncontrolled Persistent Asthma The Journal of Allergy and Clinical Immunology. 141. DOI: 10.1016/J.Jaci.2017.12.357 |
0.51 |
|
| 2018 |
Bachert C, Hellings PW, Mullol J, Naclerio RM, Hamilos DL, Gevaert P, Zhang D, Khan A, Fan C, Amin N, Hamilton JD, Swanson BN, Pirozzi G, Graham NM, Mannent L. Atopic Comorbidities and Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Who Failed Intranasal Corticosteroids Journal of Allergy and Clinical Immunology. 141: AB90. DOI: 10.1016/J.Jaci.2017.12.290 |
0.417 |
|
| 2018 |
Maspero J, Fitzgerald M, Pavord I, Wenzel S, Zhang B, Maroni J, Rowe P, Amin N, Pirozzi G, Ruddy M, Akinlade B, Graham N, Teper A. Dupilumab Reduces Severe Exacerbation Rate And Improves Lung Function In Adolescent Patients With Uncontrolled, Moderate-To-Severe Asthma: From The Liberty Asthma Quest Study Chest. 154. DOI: 10.1016/J.Chest.2018.08.022 |
0.53 |
|
| 2018 |
Castro M, Corren J, Hanania N, Pavord I, Quirce S, Thangavelu K, Rice M, O'Riordan T, Maroni J, Rowe P, Lu Y, Amin N, Ruddy M, Akinlade B, Graham N, et al. Dupilumab Efficacy In Uncontrolled, Moderate-To-Severe Allergic Asthma In The Phase 3 Liberty Asthma Quest Study Annals of Allergy Asthma & Immunology. 121. DOI: 10.1016/J.Anai.2018.09.021 |
0.579 |
|
| 2017 |
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, ... ... Amin N, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet (London, England). PMID 28478972 DOI: 10.1016/S0140-6736(17)31191-1 |
0.446 |
|
| 2017 |
Castro M, Maspero JF, Staudinger H, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, Teper A. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility European Respiratory Journal. DOI: 10.1183/1393003.Congress-2017.Pa4018 |
0.515 |
|
| 2017 |
Katial R, Joish VN, Amin N, Rowe P, Maroni J, Pirozzi G, Graham NMH, Guillonneau S, Teper A, Eckert L, Taniou C. Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa3551 |
0.578 |
|
| 2017 |
Weinstein S, Staudinger H, Guillonneau S, Taniou C, Eckert L, Joish V, Maroni J, Rowe P, Amin N, Pirozzi G, Graham N, Teper A. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa3550 |
0.58 |
|
| 2017 |
Hellings P, Bachert C, Mullol J, Hamilos D, Naclerio R, Joish V, Mannent L, Amin N, Abbe A, Taniou C, Pirozzi G, Graham N, Khan A. Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa3549 |
0.555 |
|
| 2017 |
Katelaris C, Maspero J, Jayawardena S, Rowe P, Maroni J, Pirozzi G, Amin N, Nmh G, Mannent L, Teper A. P58: Dupilumab Efficacy And Effect On Asthma Control In Patients With Uncontrolled Persistent Asthma And Comorbid Chronic Rhinosinusitis With Or Without Nasal Polyps Internal Medicine Journal. 47: 22-22. DOI: 10.1111/Imj.58_13578 |
0.563 |
|
| 2017 |
Naclerio RM, Hamilos DL, Ferguson BJ, Bachert C, Hellings PW, Mullol J, Gevaert P, Zhang D, Khan A, Fan C, Joish VN, Amin N, Pirozzi G, Graham NM, Staudinger HW, et al. Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial Journal of Allergy and Clinical Immunology. 139: AB90. DOI: 10.1016/J.Jaci.2016.12.245 |
0.331 |
|
| 2017 |
Bernstein J, Ford L, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham N, Teper A. P204 Dupilumab reduces exacerbations and improves lung function in uncontrolled persistent asthma patients across baseline exacerbations Annals of Allergy Asthma & Immunology. 119. DOI: 10.1016/J.Anai.2017.08.242 |
0.513 |
|
| 2014 |
Albrecht E, Sillanpää E, Karrasch S, Alves AC, Codd V, Hovatta I, Buxton JL, Nelson CP, Broer L, Hägg S, Mangino M, Willemsen G, Surakka I, Ferreira MA, Amin N, et al. Telomere length in circulating leukocytes is associated with lung function and disease. The European Respiratory Journal. 43: 983-92. PMID 24311771 DOI: 10.1183/09031936.00046213 |
0.323 |
|
| 2009 |
Newport S, Amin N, Dozor AJ. Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations. Pediatric Pulmonology. 44: 866-72. PMID 19670404 DOI: 10.1002/Ppul.21078 |
0.337 |
|
| 2004 |
Assefa D, Amin N, Dozor AJ. Effect of deep inspiration on airway caliber in children with asthma. Pediatric Pulmonology. 38: 406-12. PMID 15390351 DOI: 10.1002/Ppul.20038 |
0.464 |
|
| 1999 |
Sadeghi H, Stringel G, Amin N, Dozor AJ. Unsuspected foreign body aspiration and asthma in children Emergency and Office Pediatrics. 12: 126-129. |
0.321 |
|
| 1994 |
Amin N, Dozor AJ. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis. Pediatric Pulmonology. 18: 150-4. PMID 7800431 DOI: 10.1002/Ppul.1950180306 |
0.314 |
|
| Show low-probability matches. |